Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women - Concepedia

Concepedia

Publication | Closed Access

Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women

13

Citations

31

References

2004

Year

Tatjana E. Vogelvang, Judith Leurs, Marius J. van der Mooren, Velja Mijatovic, Dirk Hendriks, Simone J.M. Neele, J. C. Netelenbos, Peter Kenemans

Menopause The Journal of The North American Menopause Society

Abstract

Long-term treatment with raloxifene reduced procarboxypeptidase U plasma concentrations.

References

	Year	Citations

Page 1